S
52.95
0.00 (0.00%)
| Previous Close | 52.95 |
| Open | 52.94 |
| Volume | 1,188,554 |
| Avg. Volume (3M) | 3,364,851 |
| Market Cap | 2,759,761,920 |
| Price / Earnings (TTM) | 135.77 |
| Price / Earnings (Forward) | 13.12 |
| Price / Sales | 10.06 |
| Price / Book | 5.57 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Diluted EPS (TTM) | -4.74 |
| Total Debt/Equity (MRQ) | 22.73% |
| Current Ratio (MRQ) | 19.64 |
| Operating Cash Flow (TTM) | -89.32 M |
| Levered Free Cash Flow (TTM) | -33.98 M |
| Return on Assets (TTM) | -52.40% |
| Return on Equity (TTM) | -105.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Soleno Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.33 |
|
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.83% |
| % Held by Institutions | 109.24% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |